Screening for bladder cancer: a perspective
Screening for bladder cancer: a perspective
复制标题
DOI：
10.1007/s00345-007-0223-2
复制
发表时间：
2008-02-01
影响因子：
3.4
通讯作者：
Malats, Nuria
中科院分区：
文献类型：
--
作者：
Lotan, Yair;Svatek, Robert S.;Malats, Nuria
膀胱癌是全球男性第七大常见癌症，女性第17大常见癌症，2002年全球共有356,000例新发膀胱癌病例。它是从诊断到死亡最昂贵的癌症之一，也是美国医疗保健总支出第五昂贵的癌症之一。在膀胱癌侵袭或转移之前的早期阶段检测膀胱癌的筛查程序可以显著改善患者的发病率和总体生存率。接受广泛的筛查策略需要仔细考虑与此类政策相关的竞争风险、收益和成本。在这篇文章中，我们将回顾膀胱癌筛查的利弊，重点是成本效益和谁应该进行筛查。
Bladder cancer is the seventh most common cancer worldwide in men and the 17th in women with an overall number of 356,000 new cases of urinary bladder cancer worldwide in 2002. It is one of the most expensive cancers from diagnosis to death and the fifth most expensive cancer in terms of total medical care expenditures in the US. A screening program that resulted in detection of bladder cancer at an earlier stage, prior to muscle invasion or metastasis, could render a significant improvement in patient morbidity and overall survival. Acceptance of wide-spread screening strategies requires careful consideration of the competing risks, benefits, and costs associated with such policies. In this article, we will review the pros and cons of bladder cancer screening with a focus on cost-effectiveness and who should be screened.